AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie's rheumatoid arthritis blockbuster Humira is set for $15 billion in revenues this year, but the first biosimilars could be on the US market as early as next year. The US company had pinned ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these ...